Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NeoGenomics, Inc. (NEO : NSDQ)
 
 • Company Description   
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.

Number of Employees: 2,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.71 Daily Weekly Monthly
20 Day Moving Average: 2,337,160 shares
Shares Outstanding: 124.76 (millions)
Market Capitalization: $1,086.64 (millions)
Beta: 0.86
52 Week High: $54.74
52 Week Low: $7.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.60% -13.94%
12 Week -58.17% -54.01%
Year To Date -74.47% -68.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9490 NEOGENOMICS WAY
-
FORT MYERS,FL 33912
USA		 ph: 239-768-0600
fax: 239-690-4237		 sjones@neogenomics.com http://www.neogenomics.com
 
 • General Corporate Information   
Officers
Mark W. Mallon - Director and Chief Executive Officer
Lynn A. Tetrault - Chair of the Board
William B. Bonello - Chief Financial Officer
Bruce K. Crowther - Director
Michael A. Kelly - Director

Peer Information
NeoGenomics, Inc. (CORR.)
NeoGenomics, Inc. (RSPI)
NeoGenomics, Inc. (CGXP)
NeoGenomics, Inc. (BGEN)
NeoGenomics, Inc. (GTBP)
NeoGenomics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 64049M209
SIC: 8734
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 124.76
Most Recent Split Date: (:1)
Beta: 0.86
Market Capitalization: $1,086.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 1.25% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.00
Price/Cash Flow: 46.03
Price / Sales: 2.24
EPS Growth
vs. Year Ago Period: -400.00%
vs. Previous Quarter: -114.29%
Sales Growth
vs. Year Ago Period: 1.42%
vs. Previous Quarter: -6.81%
ROE
03/31/22 - -6.62
12/31/21 - -4.17
09/30/21 - -1.33
ROA
03/31/22 - -3.94
12/31/21 - -2.46
09/30/21 - -0.81
Current Ratio
03/31/22 - 7.93
12/31/21 - 7.81
09/30/21 - 7.66
Quick Ratio
03/31/22 - 7.64
12/31/21 - 7.54
09/30/21 - 7.42
Operating Margin
03/31/22 - -15.21
12/31/21 - -9.12
09/30/21 - -2.63
Net Margin
03/31/22 - -7.33
12/31/21 - -1.72
09/30/21 - 10.08
Pre-Tax Margin
03/31/22 - -9.69
12/31/21 - -3.11
09/30/21 - 7.57
Book Value
03/31/22 - 8.62
12/31/21 - 9.00
09/30/21 - 9.25
Inventory Turnover
03/31/22 - 13.37
12/31/21 - 13.51
09/30/21 - 12.13
Debt-to-Equity
03/31/22 - 0.50
12/31/21 - 0.48
09/30/21 - 0.47
Debt-to-Capital
03/31/22 - 33.15
12/31/21 - 32.46
09/30/21 - 31.87
 

Powered by Zacks Investment Research ©